Thermo Fisher Scientific Inc. (TMO) Shares Bought by Parkside Investments LLC

Parkside Investments LLC boosted its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 55.2% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 14,199 shares of the medical research company’s stock after buying an additional 5,050 shares during the period. Thermo Fisher Scientific accounts for approximately 1.4% of Parkside Investments LLC’s holdings, making the stock its 24th largest holding. Parkside Investments LLC’s holdings in Thermo Fisher Scientific were worth $3,177,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. K.J. Harrison & Partners Inc acquired a new position in shares of Thermo Fisher Scientific in the 3rd quarter valued at about $3,661,000. Oakworth Capital Inc. lifted its stake in shares of Thermo Fisher Scientific by 30.0% in the 3rd quarter. Oakworth Capital Inc. now owns 1,476 shares of the medical research company’s stock valued at $360,000 after purchasing an additional 341 shares in the last quarter. XR Securities LLC acquired a new position in shares of Thermo Fisher Scientific in the 4th quarter valued at about $375,000. First Trust Advisors LP lifted its stake in shares of Thermo Fisher Scientific by 92.5% in the 3rd quarter. First Trust Advisors LP now owns 303,090 shares of the medical research company’s stock valued at $73,978,000 after purchasing an additional 145,619 shares in the last quarter. Finally, Blue Chip Wealth Management Inc. lifted its stake in shares of Thermo Fisher Scientific by 26.5% in the 3rd quarter. Blue Chip Wealth Management Inc. now owns 2,154 shares of the medical research company’s stock valued at $526,000 after purchasing an additional 451 shares in the last quarter. 91.80% of the stock is currently owned by hedge funds and other institutional investors.

Thermo Fisher Scientific stock opened at $246.14 on Friday. The company has a market cap of $99.59 billion, a P/E ratio of 22.13, a P/E/G ratio of 1.63 and a beta of 1.14. The company has a current ratio of 1.71, a quick ratio of 1.23 and a debt-to-equity ratio of 0.64. Thermo Fisher Scientific Inc. has a one year low of $199.85 and a one year high of $253.91.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, January 30th. The medical research company reported $3.25 EPS for the quarter, topping the consensus estimate of $3.19 by $0.06. The firm had revenue of $6.51 billion for the quarter, compared to analyst estimates of $6.26 billion. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 12.06%. Thermo Fisher Scientific’s revenue for the quarter was up 7.6% on a year-over-year basis. During the same period in the previous year, the company posted $2.79 EPS. Sell-side analysts expect that Thermo Fisher Scientific Inc. will post 12.14 EPS for the current year.

In other Thermo Fisher Scientific news, Director Tyler Jacks sold 4,772 shares of Thermo Fisher Scientific stock in a transaction that occurred on Monday, November 19th. The stock was sold at an average price of $239.75, for a total transaction of $1,144,087.00. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CFO Stephen Williamson sold 9,500 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, December 7th. The stock was sold at an average price of $241.45, for a total value of $2,293,775.00. Following the sale, the chief financial officer now owns 44,124 shares in the company, valued at $10,653,739.80. The disclosure for this sale can be found here. Insiders have sold a total of 32,607 shares of company stock worth $7,972,085 over the last three months. 0.49% of the stock is currently owned by corporate insiders.

TMO has been the topic of several recent research reports. Barclays boosted their price target on Thermo Fisher Scientific from $275.00 to $280.00 and gave the stock an “overweight” rating in a research report on Thursday, January 3rd. Zacks Investment Research lowered Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research report on Friday, November 30th. Needham & Company LLC initiated coverage on Thermo Fisher Scientific in a research report on Wednesday, January 2nd. They set a “strong-buy” rating and a $271.00 price target on the stock. Finally, Robert W. Baird boosted their price target on Thermo Fisher Scientific from $264.00 to $270.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 30th. Three investment analysts have rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $275.70.

COPYRIGHT VIOLATION WARNING: This article was reported by WKRB News and is the sole property of of WKRB News. If you are viewing this article on another domain, it was copied illegally and reposted in violation of international copyright and trademark law. The correct version of this article can be accessed at https://www.wkrb13.com/2019/02/15/thermo-fisher-scientific-inc-tmo-shares-bought-by-parkside-investments-llc.html.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

Read More: How Short Selling Works

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.